- Home
- CMMB vs AIXC Comparison
CMMB vs AIXC Comparison
Compare CMMB & AIXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- AIXC
- Stock Information
- Founded
- CMMB 2004
- AIXC 1996
- Country
- CMMB Israel
- AIXC United States
- Employees
- CMMB N/A
- AIXC N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- AIXC Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- AIXC Health Care
- Exchange
- CMMB Nasdaq
- AIXC Nasdaq
- Market Cap
- CMMB 13.8M
- AIXC 13.1M
- IPO Year
- CMMB N/A
- AIXC N/A
- Fundamental
- Price
- CMMB $2.54
- AIXC $2.53
- Analyst Decision
- CMMB Strong Buy
- AIXC
- Analyst Count
- CMMB 2
- AIXC 0
- Target Price
- CMMB $26.50
- AIXC N/A
- AVG Volume (30 Days)
- CMMB 80.5K
- AIXC 258.2K
- Earning Date
- CMMB 11-20-2025
- AIXC 11-21-2025
- Dividend Yield
- CMMB N/A
- AIXC N/A
- EPS Growth
- CMMB N/A
- AIXC N/A
- EPS
- CMMB N/A
- AIXC N/A
- Revenue
- CMMB N/A
- AIXC N/A
- Revenue This Year
- CMMB N/A
- AIXC N/A
- Revenue Next Year
- CMMB N/A
- AIXC N/A
- P/E Ratio
- CMMB N/A
- AIXC N/A
- Revenue Growth
- CMMB N/A
- AIXC N/A
- 52 Week Low
- CMMB $2.36
- AIXC $1.61
- 52 Week High
- CMMB $9.84
- AIXC $8.81
- Technical
- Relative Strength Index (RSI)
- CMMB 42.45
- AIXC N/A
- Support Level
- CMMB $2.36
- AIXC N/A
- Resistance Level
- CMMB $2.85
- AIXC N/A
- Average True Range (ATR)
- CMMB 0.20
- AIXC 0.00
- MACD
- CMMB -0.02
- AIXC 0.00
- Stochastic Oscillator
- CMMB 32.71
- AIXC 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.